Eventide Asset Management - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 152 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.3%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q2 2024$123,137,155
-5.9%
3,327,132
+6.7%
2.11%
+2.7%
Q1 2024$130,908,081
-9.1%
3,119,087
-14.1%
2.05%
-12.6%
Q4 2023$143,966,316
+227.0%
3,630,013
+126.9%
2.35%
+197.1%
Q3 2023$44,032,000
-5.8%
1,600,000
+16.1%
0.79%
+0.1%
Q2 2023$46,746,718
-5.7%
1,377,7400.0%0.79%
-13.1%
Q1 2023$49,571,085
-24.0%
1,377,740
-5.8%
0.91%
-29.3%
Q4 2022$65,208,139
+29.5%
1,463,050
-18.3%
1.29%
+29.8%
Q3 2022$50,367,000
+29.2%
1,791,800
+23.9%
0.99%
+18.8%
Q2 2022$38,976,000
-20.8%
1,445,7000.0%0.83%
+8.0%
Q1 2022$49,241,000
+2.9%
1,445,700
+16.7%
0.77%
+26.1%
Q4 2021$47,871,000
-21.4%
1,238,900
+9.8%
0.61%
-23.8%
Q3 2021$60,901,000
-13.6%
1,128,000
-46.5%
0.80%
-15.2%
Q2 2021$70,522,000
+66.0%
2,108,908
+2.3%
0.95%
+50.3%
Q1 2021$42,486,000
+32.0%
2,062,433
+12.3%
0.63%
+27.5%
Q4 2020$32,186,000
+328.7%
1,837,108
+262.9%
0.49%
+236.1%
Q3 2020$7,507,000
+24.6%
506,179
+9.2%
0.15%
+12.2%
Q2 2020$6,023,000463,3350.13%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q2 2023
NameSharesValueWeighting ↓
Kynam Capital Management, LP 753,034$25,648,0008.32%
Octagon Capital Advisors LP 761,398$25,933,0005.61%
ACUTA CAPITAL PARTNERS, LLC 322,898$10,998,0005.14%
Tri Locum Partners LP 383,319$13,056,0005.10%
VR Adviser, LLC 865,116$29,466,0004.77%
TSP Capital Management Group, LLC 269,045$9,164,0003.10%
Ikarian Capital, LLC 595,500$20,282,0002.67%
Ikarian Capital, LLC 537,958$18,323,0002.41%
Ghost Tree Capital, LLC 300,000$10,218,0002.22%
Redmile Group, LLC 2,046,269$69,696,0002.18%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders